中国实用妇科与产科杂志2025，Vol.41Issue(10)：972-975,4.DOI:10.19538/j.fk2025100104
妇科恶性肿瘤患者辅助治疗期间的贫血管理
Management of anemia during adjuvant therapy in patients with gynecologic malignancies
周念 1张国楠2
作者信息
- 1. 西南医科大学附属医院肿瘤科,四川泸州 646000
- 2. 西南医科大学附属医院肿瘤科,四川泸州 646000||四川省肿瘤医院(电子科技大学附属肿瘤医院),四川成都 610041
- 折叠
摘要
Abstract
Anemia frequently occurs in gynecologic malignancy patients undergoing adjuvant therapy,with iron-deficiency anemia(IDA)being the most prevalent.Anemia reduces patients' tolerance to treatment,leading to therapy delays,dose reductions,or even discontinuation.This may result in chemotherapy resistance and decreased radiotherapy sensitivity.Correcting anemia can improve prognosis,so standardized anemia management is essential.Common therapeutic approaches include iron supplementation,erythropoiesis-stimulating agents(ESAs),and blood transfusions.Among these,third-generation intravenous iron preparations have emerged as a new option in the anemia management in adjuvant therapy for patients with gynecological malignancies due to their rapid iron repletion,reduced transfusion risks,and the convenience of single-dose administration.关键词
妇科恶性肿瘤/肿瘤相关性贫血/肿瘤化疗相关性贫血/缺铁性贫血/静脉铁剂Key words
gynecologic malignancies/cancer-related anemia/chemotherapy-induced anemia/iron-deficiency anemia/intravenous iron分类
临床医学引用本文复制引用
周念,张国楠..妇科恶性肿瘤患者辅助治疗期间的贫血管理[J].中国实用妇科与产科杂志,2025,41(10):972-975,4.
